Responses
Regular and young investigator award abstracts
Clinical trials in progress
362 A PhII study of bemcentinib, a first-in-class selective AXL kinase inhibitor, in combination with pembrolizumab in pts with previously-treated advanced NSCLC: Updated clinical & translational analysis
Compose a Response to This Article
Other responses
No responses have been published for this article.
